Who is sponsoring NCT05872841?

NCT05872841 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT05872841?

Interventions in NCT05872841: Recombinant human adenovirus type 5 + TACE.

What condition does NCT05872841 study?

NCT05872841 studies Primary Hepatocellular Carcinoma, Portal Vein Thrombosis.

Is NCT05872841 still recruiting?

NCT05872841 is currently status unknown. Last updated 24 May 2023.

Last reviewed 2023-05-24 · How we verify

NCT05872841

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis

Status unknown Phase 2 Last updated 24 May 2023

What this trial tests

Phase 2 trial testing Recombinant human adenovirus type 5 + TACE in Primary Hepatocellular Carcinoma in 38 participants. Status unknown.

Timeline

1 June 2023

Primary endpoint
31 December 2024

30 June 2025

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	1 June 2023
Primary completion	31 December 2024
Estimated completion	30 June 2025

Drugs / interventions tested

Recombinant human adenovirus type 5 + TACE — full drug profile →

Conditions studied

Primary Hepatocellular Carcinoma — all drugs for Primary Hepatocellular Carcinoma →
Portal Vein Thrombosis — all drugs for Portal Vein Thrombosis →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Adults 18 to 75, any sex, with Primary Hepatocellular Carcinoma or Portal Vein Thrombosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is the first to compare the efficacy and safety of recombinant human adenovirus type 5 injection via hepatic artery infusion combined with TACE-based combination therapy for the treatment of patients with stage IIIa primary hepatocellular carcinoma with portal vein carcinoma thrombosis, providing a safe and reliable treatment method for the clinical treatment of this group of patients, and also providing a reference and basis for the treatment of other tumors with this new treatment model.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Evolving Horizons: Adenovirus Vectors' Timeless Influence on Cancer, Gene Therapy and Vaccines.
Trivedi PD, Byrne BJ, Corti M. · · 2023 · cited 22× · PMID 38140619 · DOI 10.3390/v15122378
Research and Clinical Progress of Therapeutic Tumor Vaccines.
Dong C, Li Z, Tan D, Sun H, et al · · 2025 · cited 3× · PMID 40733649 · DOI 10.3390/vaccines13070672
Gene Therapy Strategies for Hepatocellular Carcinoma (HCC): Current Landscape and Future Directions.
Ermi AG, Younis RM, Rodriguez K, Sarkar D. · · 2025 · PMID 41300975 · DOI 10.3390/cancers17223608
Oncolytic virus therapy in hepatocellular carcinoma.
Ye Y, Liu Y. · · 2025 · PMID 40612869 · DOI 10.32604/or.2025.061857

Verify or expand the search:

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05872841 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 24 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05872841.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing